GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BrainsWay Ltd (NAS:BWAY) » Definitions » Capex-to-Revenue

BrainsWay (BrainsWay) Capex-to-Revenue : 0.05 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is BrainsWay Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

BrainsWay's Capital Expenditure for the three months ended in Dec. 2023 was $-0.44 Mil. Its Revenue for the three months ended in Dec. 2023 was $9.03 Mil.

Hence, BrainsWay's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.05.


BrainsWay Capex-to-Revenue Historical Data

The historical data trend for BrainsWay's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BrainsWay Capex-to-Revenue Chart

BrainsWay Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.11 0.08 - 0.08

BrainsWay Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.19 0.06 0.05

Competitive Comparison of BrainsWay's Capex-to-Revenue

For the Medical Devices subindustry, BrainsWay's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BrainsWay's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BrainsWay's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where BrainsWay's Capex-to-Revenue falls into.



BrainsWay Capex-to-Revenue Calculation

BrainsWay's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-2.387) / 31.785
=0.08

BrainsWay's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.442) / 9.029
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BrainsWay  (NAS:BWAY) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


BrainsWay Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of BrainsWay's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


BrainsWay (BrainsWay) Business Description

Traded in Other Exchanges
Address
19 Hartum Street, 3rd Floor, Bynet Building, Har Hotzvim, Jerusalem, ISR, 9777518
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.